Author Archives: Adam Rosenberg

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After decades of challenges in neuroscience research and development, there is new hope that we can design better clinical

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Disappointing results in Alzheimer’s clinical trials seem to be announced on an almost monthly, and sometimes weekly basis: Merck’s

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In 2015 I went to both the JPMorgan and CES conferences, back to back, and attended numerous can’t-miss dinners,

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC.   In my February 2016 post, I wrote “if some of the current generation of high-profile,

This post was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Those of us in biotech tend to focus our attention on drug discovery and development, but it is also

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. As a controlled experiment, try placing a tape recorder, rotary phone or record album in front of an 8

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After a long, challenging period for CNS R&D – marked by late-stage clinical failures, mass layoffs, and limited early-stage